Success Story: NIW Approved! Our Expert Team Helped an Iranian Associate Professor Achieve U.S. Immigration Success

Case Summary:     

We are pleased to share the success story of an EB-2 NIW (National Interest Waiver) approval granted to a pharmacology expert whose research is helping advance the development of novel therapeutic agents for pain management and mental health disorders. At the time of filing, the client was engaged in research aimed at improving drug efficacy while reducing side effects, to create more effective treatment options for chronic neuropathic pain, mitigating morphine tolerance, and addressing depressive disorders.

Research Focus and Contributions:
 The petition demonstrated that the client’s proposed endeavor focuses on designing and applying innovative pharmaceutical agents as adjunctive therapies to conventional treatments. Their work addresses significant gaps in current treatment modalities by:

• Developing compounds with enhanced analgesic effects while minimizing dependency risks.
• Investigating mechanisms to prevent morphine tolerance in patients undergoing long-term opioid therapy.
• Creating targeted therapeutic approaches to manage depressive disorders with improved safety profiles.

Research Impact and Scientific Contributions:
 To establish the substantial merit and national importance of the client’s work, the petition emphasized:

• Publications: 49 peer-reviewed journal articles (15 first-authored), 5 first-authored abstracts, and 1 first-authored book chapter.
• Citations: 1,942 citations on Google Scholar, demonstrating the broad recognition and influence of the client’s research.
• Peer Recognition: Findings have been frequently referenced by other scientists and clinicians working to enhance pain management, mental health therapies, and pharmacological safety.

Well Positioned to Advance the Proposed Endeavor:
 The petition demonstrated that the client’s Ph.D. in pharmacology, combined with an extensive publication record and history of high-impact research, has uniquely prepared them to advance pharmaceutical science in areas of urgent national need. Their prior breakthroughs form a robust platform for future innovations that will influence both clinical practice and public health outcomes.

NIW Approval and Outlook:
 Approved in February 2025, the NIW petition was granted in recognition of the client’s demonstrated expertise, proven research impact, and ability to contribute solutions to critical healthcare challenges. NAILG is proud to have represented this client and looks forward to the continued success of their work in developing safer and more effective therapies.